Earnings History Data for Solid Biosciences (SLDB) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Solid Biosciences

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-03-2024	PM		SLDB	Solid Biosciences	230.00	-1.00	-1.01	0.00	Solid Biosciences reports Q4 results [3/13/2024 7:58 AM]	12.19	0.79 (6.89%)	11.00	-0.40 (-3.51%)	1.81 - 12.28	403,852	190,000	4,292
Solid Biosciences reports Q4 results [3/13/2024 7:58 AM] Solid Biosciences files $300M mixed securities shelf [3/13/2024 9:33 AM]
08-11-2023	AH		SLDB	Solid Biosciences	55.00	-1.05	-1.20	0.00	Solid Biosciences reports Q3 results [11/8/2023 5:38 PM]	2.13	-0.66 (-23.66%)	0.0	0.0 (0.00%)	1.81 - 8.20	29,831	40,000	0
Solid Biosciences reports Q3 results [11/8/2023 5:38 PM]
14-08-2023	AH		SLDB	Solid Biosciences	75.00	-1.25	-1.52	0.00	Solid Biosciences reports Q2 results [8/14/2023 5:33 PM]	3.74	-0.11 (-2.86%)	3.93	0.08 (2.08%)	3.40 - 14.25	7,480	10,000	382
Solid Biosciences reports Q2 results [8/14/2023 5:33 PM]
11-05-2023	PM		SLDB	Solid Biosciences Inc.	105.89	-1.54	-1.83	-3.30	Solid Biosciences reports Q1 results [5/11/2023 9:21 AM]	6.44	0.24 (3.87%)	5.99	0.05 (0.84%)	3.40 - 14.25	18,739	20,000	929
Solid Biosciences reports Q1 results [5/11/2023 9:21 AM]
23-03-2023	PM		SLDB	Solid Biosciences	27.00	-0.68	-2.70	0.00	Solid Biosciences reports Q4 results [3/23/2023 8:44 AM]	3.70	-0.08 (-2.12%)	3.73	-0.05 (-1.32%)	3.40 - 19.80	97,578	70,000	350
Solid Biosciences reports Q4 results [3/23/2023 8:44 AM]
10-11-2022	PM	7:55 AM ET (Nov 10)	SLDB	Solid Biosciences Inc.	47.01	-2.71	-2.59	-2.40	Solid Biosciences reports Q3 results [11/10/2022 8:41 AM]	6.53	0.17 (2.67%)	6.35	-0.01 (-0.16%)	5.89 - 35.25	26,047	70,000	2,001
Solid Biosciences reports Q3 results [11/10/2022 8:41 AM] Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results [Nov-10-22 07:34AM]
11-08-2022	PM		SLDB	Solid Biosciences	86.00	-0.22	-0.21	0.00	Solid Biosciences reports Q2 results [8/11/2022 8:45 AM]	0.7731	0.02 (2.88%)	0.80	0.05 (6.47%)	0.42 - 3.42	701,158	450,000	72,636
Solid Biosciences reports Q2 results [8/11/2022 8:45 AM] Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results [Aug-11-22 07:53AM]
27-04-2022	PM	8:10 AM ET (Apr 27)	SLDB	Solid Biosciences Inc.	89.45	-0.22	-0.18	-0.19		0.64	-0.14 (-17.42%)	0.79	0.01 (1.61%)	0.64 - 5.46	1,417,712	400,000	12,940
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy [Apr-27-22 07:30AM] Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates [Apr-27-22 10:35AM]
03-11-2021	PM		SLDB	Solid Biosciences	236.00	-0.16	-0.19	0.00	Solid Biosciences EPS beats by $18.20, beats on revenue [11/3/2021 8:44 AM]	2.36	0.20 (9.26%)	2.15	-0.01 (-0.46%)	1.82 - 11.58	1,225,124	1,380,000	11,576
Warning: SLDB is at high risk of performing badly [11/3/2021 5:04 AM] Regenxbio-Solid Biosciences' PDC releases white paper for AAV gene therapy development [11/2/2021 8:15 AM] Solid Biosciences EPS beats by $18.20, beats on revenue [11/3/2021 8:44 AM] Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results [Nov-03-21 07:05AM] Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development [Nov-02-21 07:30AM] Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Tops Revenue Estimates [Nov-03-21 08:35AM]
16-08-2021	AH	After the close (Aug 16)	SLDB	Solid Biosciences Inc.	300.00	-0.17	-0.18	0.00	Solid Biosciences EPS beats by $0.01, beats on revenue [8/16/2021 4:42 PM]	2.57	0.06 (2.19%)	2.47	-0.04 (-1.59%)	1.93 - 11.58	377,899	450,000	1,326
Solid Biosciences EPS beats by $0.01, beats on revenue [8/16/2021 4:42 PM] Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results [Aug-16-21 04:11PM] Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates [Aug-16-21 06:45PM]
05-11-2020	PM	0:00 AM ET (Nov 5)	SLDB	Solid Biosciences Inc.	178.50	-0.44	-0.31	-0.67	Solid Biosciences EPS misses by $0.10 [11/5/2020 7:18 AM]	3.24	0.0 (0.00%)	3.23	-0.01 (-0.31%)	1.93 - 11.78	270,966	1,666,803	582